Jazz Pharmaceuticals (JAZZ) Total Current Liabilities (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Total Current Liabilities of $2.2 billion for Q1 2026, up 83.75% year-over-year from $1.2 billion in Q1 2025, and little changed quarter-over-quarter from $2.2 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Total Current Liabilities (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $2.2 billion for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 83.75% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $2.2 billion (up 83.75% YoY), while the FY2025 annual figure was $2.2 billion, up 115.92% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $2.2 billion, roughly flat from $2.2 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $2.3 billion in Q3 2025, with the low at $705.4 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $1.2 billion (2025), against an average of $1.4 billion.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 34.54% in 2024, then surged 120.79% in 2025.
- Jazz Pharmaceuticals' Total Current Liabilities stood at $933.2 million in 2022, then jumped by 64.67% to $1.5 billion in 2023, then tumbled by 32.42% to $1.0 billion in 2024, then soared by 115.92% to $2.2 billion in 2025, then increased by 0.18% to $2.2 billion in 2026.
- Business Quant data shows JAZZ's Total Current Liabilities at $2.2 billion in Q1 2026, $2.2 billion in Q4 2025, and $2.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 2.23 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.23 Bn |
| Mar 31, 2026 | 2.25 Bn |
| Dec 31, 2025 | 2.24 Bn |
| Sep 30, 2025 | 2.27 Bn |
| Jun 30, 2025 | 2.07 Bn |
| Mar 31, 2025 | 1.22 Bn |
| Dec 31, 2024 | 1.04 Bn |
| Sep 30, 2024 | 1.03 Bn |
| Jun 30, 2024 | 1.56 Bn |
| Mar 31, 2024 | 1.56 Bn |
| Dec 31, 2023 | 1.54 Bn |
| Sep 30, 2023 | 1.57 Bn |
| Jun 30, 2023 | 945.27 Mn |
| Mar 31, 2023 | 908.90 Mn |
| Dec 31, 2022 | 933.19 Mn |
| Sep 30, 2022 | 812.95 Mn |
| Jun 30, 2022 | 705.44 Mn |
| Mar 31, 2022 | 737.41 Mn |
| Dec 31, 2021 | 809.30 Mn |
| Sep 30, 2021 | 735.05 Mn |